Described as “deliberately challenging”, the new time-to-treatment targets published by the Vascular Society of Great Britain and Ireland (VSGBI), as part of the Peripheral Arterial Disease Quality Improvement Framework, have prompted a number of different measures in the UK for the treatment of patients with chronic limb-threatening ischaemia (CLTI).
Speaking at the VSGBI’s annual meeting (27–29 November, Manchester, UK), Andrew Nickinson (University of Leicester, Leicester, UK) spoke about the potential benefits offered by a specialist, vascular limb salvage (VaLS) clinic, as well as missed opportunities for the timely recognition of CLTI within primary care. He said: “I think we are increasingly recognising that delayed diagnosis and management of CLTI are detrimental to outcomes, and there is a growing effort to try and reduce time-to-treatment after patients have been referred to us as vascular surgeons.”
Benefits of a limb salvage clinic
Focusing on the work done in Leicester for patients with CLTI, Nickinson discussed how “a nurse-led, open access, outpatient limb salvage clinic” has attempted to provide a one-stop assessment for patients. According to the speaker, patients referred into the clinic receive a detailed vascular assessment—including duplex arterial ultrasound—within the same day, before a decision regarding next steps is made “there and then” by a vascular consultant.
Moreover, it was said that these patients have access to dedicated outpatient angiography slots, “with the aim of this project being to treat patients in 10 days or less of initial referral”. In order to establish whether or not this limb salvage service can help to meet time-to-treatment targets, Nickinson explained that an investigation evaluating one-year amputation outcomes was conducted.
“To do this, we interrogated our prospectively maintained clinic database and included all patients who were managed with chronic limb threatening ischaemia or diabetic foot ulceration over a one-year period from the inception of the clinic (February 2018 to February 2019),” commented the speaker.
As part of the study, two comparative cohorts were formed; pre-clinic patients assessed prior to the start of the clinic (from May 2017 to February 2018), and also patients who were managed through alternative pathways, while the clinic was functioning. In terms of the latter group, Nickinson added: “This included for example, the people who still made it through to the elective outpatient setting.” Primary outcomes for the investigation were the rate of major amputation and amputation-free survival at 12 months.
“In total, we assessed 294 patients in the first year of the clinic, of which 222 had chronic limb threatening ischaemia or neuropathic diabetic foot ulceration. From the patients diagnosed with CLTI, approximately 75% went on to have a revascularisation procedure,” Nickinson revealed.
Regarding times to treatment, as Nickinson highlighted, the clinic was able to assess patients, on average, within two days of initial referral, and move them onwards to revascularisation within six days of assessment. “If you drill into those numbers further,” Nickinson continued, “this actually equates to five working days, given that the clinic does not work, at the moment, on weekends”.
“Looking at our primary outcome, which was major amputation at 12 months, those patients in the VaLS clinic had half the rate of major amputations compared to the other comparative cohorts, and this result was found to be statistically significant. The trend continued for amputation-free survival also and, in absolute terms, there was a 15% improvement, which was again statistically significant.”
Nickinson did note both the strengths and limitations of the data, as while this was “one of the few studies which actually provides comparative institutional data to compare our findings”, there is a possibility of selection performance bias in this cohort, as well as some crossover between these groups. Returning to the original question, Nickinson said of the clinic’s ability to improve time to treatment, “I think our early results indicate that yes, it can. What is more, this service potentially provides a blueprint for other trusts to meet these challenging targets. We have also shown that the clinic can improve amputation-related outcomes for patients”.
Source VascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389